FUNDAMENTALS |
MarketCap: |
175 448 mill
|
EPS: |
0.530
|
P/E: |
230.53
|
Earnings Date: |
Mar 30, 2023 |
SharesOutstanding: |
1 435.98 mill
|
Avg Daily Volume: |
0.191 mill
|
QUARTER GROWTHS |
|
4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 |
Revenue | | | | | | |
Gr.Profit | | | | | | |
Ebit | | | | | | |
Asset | | | | | | |
Debt | | | | | | |
PE RATIO: COMPANY / SECTOR |
14.94x
|
Company: PE 230.53 | sector: PE 15.43
|
PE RATIO: COMPANY / INDUSTRY |
2.62x
|
Company: PE 230.53 | industry: PE 87.83
|
DISCOUNTED CASH FLOW VALUE |
N/A
|
N/A
|
Expected Trading Range (DAY) |
$ 120.27 - 124.09
( +/- 1.56%)
|
ATR Model: 14 days
|
Insider Trading
Date |
Person |
Action |
Amount |
type |
2024-01-12 | Fitzgerald Joseph Michael | Sell | 11 660 | Common Stock |
2024-01-09 | Mirviss Jeffrey B. | Buy | 15 172 | Common Stock |
2024-01-09 | Mirviss Jeffrey B. | Sell | 15 172 | Common Stock |
2024-01-09 | Mirviss Jeffrey B. | Sell | 15 172 | Stock Option (Right to Buy) |
2024-01-04 | Mirviss Jeffrey B. | Buy | 15 000 | Common Stock |
INSIDER POWER |
-33.84
|
Last
100 transactions |
Buy:
835 783 | Sell:
1 712 211 |
Forecast:
01:40 - $126.72
Live Trading Signals (every 1 min)
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals |
RSI 21 |
|
SMA |
|
Trend |
|
Trend 2 |
|
Trend 3 |
|
MACD |
|
Volume Signals |
Price |
$122.18 (2.37% )
|
Volume |
2.06 mill
|
Avg. Vol. |
0.191 mill
|
% of Avg. Vol |
1 073.77 %
|
Signal 1: |
|
Signal 2: |
|
Last 10 Buy & Sell Signals For BSX-PA
0 Signals |
Accuracy: 0.00% | Accuracy
Buy: 0.00% | Accuracy
Sell: 0.00%
Avg return
buy: 0.00 % | Avg return
sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.